Search Results

INCLUSION: 1. Provision of fully informed consent prior to any study specific procedures Histologic or cytologic confirmation of exocrine pancreatic adenocarcinoma Locally advanced and/or metastatic disease by imaging (CT or MRI or EUS) confirmed by biopsy if possible. Acquisition of tissue is encouraged if the patient gives informed consent 2. Measurable disease according to RECIST criteria 3. Willingness to undergo a thin needle core biopsy for tumor tissue if it is easily accessible if the initial tissue for diagnosis is not sufficient for additional research marker analysis (not required for patients with known germline mutations in BRCA2 or PALB2) 4. Prior neoadjuvant or adjuvant therapy is acceptable, as long as no more than one drug of the ICM regimen was used 5. No prior chemotherapy for advanced pancreatic cancer with Olaparib, Irinotecan, cisplatin or Mitomycin C: (Gemzar, Tarceva, and 5-FU or xeloda oxaliplatin and taxotere permitted) 6. 3 or more weeks since last surgery, radiation, chemotherapy mentioned in #6 above or investigational therapies 7. No prior PARP inhibitors 8. Negative HCG pregnancy test for females or current breastfeeding 9. ECOG status less than 3 (0, 1, 2 acceptable) 10. Life expectancy greater than 3 months 11. Patients must have normal organ and bone marrow function measured within 7 days prior to administration of study treatment 12. Age greater than 18 13. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations 14. Evidence of non-childbearing status for women of childbearing potential, or postmenopausal status: negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on day 1 EXCLUSION: 1. Patients with 2nd primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for â?¥ 5 years 2. Patients receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), less than 3 weeks from the last dose prior to study treatment 3. For patients who have locally advanced pancreatic cancer only, if they have received therapeutic doses of radiation therapy to their pancreatic bed (~50 Gy) for treatment of their locally advanced pancreatic cancer 4. Patients having already had prior chemotherapy for more than 6 months for their advanced pancreatic cancer (not including adjuvant/neoadjuvant) 5. Patients receiving the certain classes of inhibitors of CYP3A4 6. Unresolved toxicities ( greater than CTCAE grade 2) caused by previous cancer therapy 7. Patients with known brain metastases. A scan to confirm the absence of brain metastases is not required 8. Major surgery less than 3weeks of starting study treatment and patients must have recovered from any effects of any major surgery 9. Patients considered a poor medical risk due to serious, uncontrolled medical disorders, non-malignant systemic disease or active, uncontrolled infection 10. Patients unable to swallow oral medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication 11. Breast feeding women 12. Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV) 13. Patients with known active hepatic disease (i.e., Hepatitis B or C) 14. Patients with a known hypersensitivity to Olaparib or any of the excipients of the product or history of severe allergic reactions to platinums or chemotherapy 15. Patients with uncontrolled seizures 16. Grade 2 neuropathy at entry from any etiology, including diabetes (in view of Irinotecan) 17. Prior episodes of recurrent deep vein thrombosis or Trousseauâ??s Syndrome unless the patient is anticoagulated